Escolar Documentos
Profissional Documentos
Cultura Documentos
www.cochranelibrary.com
[Intervention Review]
Contact address: Alvaro Figueredo, Hamilton Regional Cancer Centre, McMaster Univ., Dept. of Clin. Epid. and Stat. 699 Concession
Street, Hamilton, Ontario, L8V 5C2, Canada. alvaro.figueredo@hrcc.on.ca.
Editorial group: Cochrane Colorectal Cancer Group.
Publication status and date: Edited (no change to conclusions), published in Issue 4, 2008.
Review content assessed as up-to-date: 30 April 2008.
Citation: Figueredo A, Coombes ME, Mukherjee S. Adjuvant Therapy for completely resected Stage II Colon Cancer. Cochrane
Database of Systematic Reviews 2008, Issue 3. Art. No.: CD005390. DOI: 10.1002/14651858.CD005390.pub2.
Copyright 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ABSTRACT
Background
: Colon cancer is potentially curable by surgery. Although adjuvant chemotherapy benefits patients with stage III disease, there is
uncertainty of such benefit in stage II colon cancer. A systematic review of the literature was performed to better define the potential
benefits of adjuvant therapy for patients with stage II colon cancer.
Objectives
: To determine the effects of adjuvant therapy on overall survival and disease-free survival in patients with stage II colon cancer.
Search methods
: Ovid MEDLINE(R) (1986-2007), EMBASE (1980-2007), and EBM Reviews - Cochrane Central Register of Controlled Trials (
to 2007) were searched using the medical headings colonic neoplasms, colorectal neoplasms, adjuvant chemotherapy, adjuvant
radiotherapy and immunotherapy, and the text words colon cancer and colonic neoplasms. In addition, proceedings from the
annual meetings of the American Society of Clinical Oncology and the European Society of Medical Oncology (1996 to 2004) as well
as personal files were searched for additional information.
Selection criteria
: Randomized trials or meta-analyses containing data on stage II colon cancer patients undergoing adjuvant therapy versus surgery
alone.
Data collection and analysis
: Three reviewers summarized the results of selected studies. The main outcomes of interest were overall and disease-free survival,
however, data on toxicity and treatment delivery were also recorded.
Main results
: With regards to the effect of adjuvant therapy on stage II colon cancer, the pooled relative risk ratio for overall survival was 0.96 (95%
confidence interval 0.88, 1.05). With regards to disease-free survival, the pooled relative risk ratio was 0.83 (95% confidence interval
0.75, 0.92).
Adjuvant Therapy for completely resected Stage II Colon Cancer (Review)
Copyright 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Authors conclusions
: Although there was no improvement in overall survival in the pooled analysis, we did find that disease-free survival in patients with
stage II colon cancer was signficantly better with the use of adjuvant therapy. It seems reasonable to discuss the benefits of adjuvant
systemic chemotherapy with those stage II patients who have high risk features, including obstruction, perforation, inadequate lymph
node sampling or T4 disease. The co-morbidities and likelihood of tolerating adjuvant systemic chemotherapy should be considered
as well. There exists a need to further define which high-risk features in stage II colon cancer patients should be used to select patients
for adjuvant therapy. Also, researchers must continue to search for other therapies which might be more effective, shorter in duration
and less toxic than those available today.